Pharmather Files for FDA Orphan Drug Designation Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson’s Disease Pharmather has filed an application with the FDA for Orphan Drug Designation, which is reserved for rare diseases.
The use-case in question is ketamine for the treatment of levodopa-induced dyskinesia, which is associated with Parkinson’s Disease.
Full Press Release